

| SCOPE: ALS, CCT | |
|----------------------|---|
| MEDICATION: | MIDAZOLAM (Versed) |
| INTERVENTION: | <p><u>Classification:</u> Anticonvulsant; Benzodiazepine</p> <p><u>Actions:</u> The actions of benzodiazepines are mediated through the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which is one of the major inhibitory neurotransmitters in the brain. Benzodiazepines are believed to increase the activity of GABA, thereby calming the patient, relaxing skeletal muscles, and, in high doses, producing sleep and respiratory depression. The effects of Versed on the CNS are dependent on the dose, the route, the presence of other medications, and underlying medical conditions</p> <p><u>Contraindications:</u></p> <ul style="list-style-type: none"> • Known sensitivity • Narrow-angle glaucoma <p><u>Precautions:</u></p> <ul style="list-style-type: none"> • Elderly or debilitated may be particularly sensitive to the effects • Caution in decreased perfusion states or with hypotension • Potentiates the effect other CNS depressants, hypnotics and narcotics • PREGNANCY RISK FACTOR: D <p><u>Dosage:</u></p> <p>I. <u>Anxiolysis:</u></p> <ol style="list-style-type: none"> a. Adult: <ol style="list-style-type: none"> i. IV/IO: 1-4 mg every 15-30 min ii. IN: 2-5 mg x1 b. Pediatric: <ol style="list-style-type: none"> i. IV/IO: 0.1 mg/kg every 15-30 min (max single dose 4 mg) ii. IN: 0.2 mg/kg every 5-15 min (max single dose 5 mg) <p>II. <u>Seizures:</u></p> <ol style="list-style-type: none"> a. Adult <ol style="list-style-type: none"> i. IV/IO/IM: 1-4 mg, repeat x2 ii. IN: 2-5 mg, repeat x2 b. Pediatric <ol style="list-style-type: none"> i. IV/IO/IN: 0.2 mg/kg <p>III. <u>Intractable Nausea and Vomiting:</u></p> <ol style="list-style-type: none"> a. Adult: <ol style="list-style-type: none"> i. IV/IO: 1-4 mg every 15-30 min b. Pediatric: <ol style="list-style-type: none"> i. IV/IO: 0.1 mg/kg every 15-30 min (max single dose 4 mg) <p><u>Onset of Action:</u> IV 1-3 minutes, IM 5-15 minutes, IN ~5 minutes</p> <p><u>Duration:</u> IV <2 hours, IM 2-6 hours, IN ~20 minutes</p> |

If this is a patient care policy, the information contained herein is used to provide guidance in the care of patients, but should not, and does not replace or preclude the use of clinical judgment.

| FOR OFFICE USE ONLY | |
|--------------------------|----------------|
| Originator: | Original Date: |
| Revised Date: | |
| Effective Date: 06/01/18 | Page 1 of 2 |

| | |
|--|---|
| | <p><u>Adverse Effects:</u> Respiratory depression, apnea, laryngospasm, hypotension, excessive salivation, nausea and vomiting, retrograde amnesia, euphoria, hallucinations, confusion, lethargy, drowsiness, ataxia, blurred vision</p> <p><u>Special Considerations:</u></p> <ol style="list-style-type: none">I. Administer over at least 2 minutes and allow an additional 2 or more minutes to fully evaluate the sedative effect |
|--|---|